Scaling Production and Managing Risks

Mesenchymal stromal/stem cells (MSCs) are in the forefront of cell therapies for COVID-19 treatment. However, the current COVID-19 pandemic requires rapid deployment of resources that can provide immediate access to MSC based therapeutics.

This webinar will cover challenges and options available for cell therapy product developers in scaling production, including industry best practices that will deliver rapid, safe, and cost-effective solutions to meet this crisis demand.

What you will learn:

true-signCurrent state of MSC therapies for COVID-19: on-going trials and clinical evidence from ARDS experience

true-signCurrent limitations and development of technology platforms to support future MSC manufacturing needs

true-signConsiderations in manufacturing readiness to support cGMP manufacturing of MSCs


Submit Form below to View Recording!